Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
暂无分享,去创建一个
D. Niederwieser | H. Gadner | G. Gastl | J. Thaler | H. Silly | A. Lang | T. Fluckinger | H. Huber | H. Seewann | C. Abbrederis